[go: up one dir, main page]

DE69627160D1 - Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma-butyrobetain für die behandlung von herz-gefäss-erkrankungen - Google Patents

Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma-butyrobetain für die behandlung von herz-gefäss-erkrankungen

Info

Publication number
DE69627160D1
DE69627160D1 DE69627160T DE69627160T DE69627160D1 DE 69627160 D1 DE69627160 D1 DE 69627160D1 DE 69627160 T DE69627160 T DE 69627160T DE 69627160 T DE69627160 T DE 69627160T DE 69627160 D1 DE69627160 D1 DE 69627160D1
Authority
DE
Germany
Prior art keywords
trimethylhydrazinium
gamma
pct
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69627160T
Other languages
English (en)
Other versions
DE69627160T2 (de
Inventor
Ivars Kalvinsh
Maris Veveris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grindeks JSC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69627160D1 publication Critical patent/DE69627160D1/de
Application granted granted Critical
Publication of DE69627160T2 publication Critical patent/DE69627160T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69627160T 1995-08-21 1996-08-20 Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma-butyrobetain für die behandlung von herz-gefäss-erkrankungen Expired - Lifetime DE69627160T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LV950256 1995-08-21
LVP-95-256A LV11728B (en) 1995-08-21 1995-08-21 Pharmaceutical composition
PCT/LV1996/000002 WO1997006794A1 (en) 1995-08-21 1996-08-20 Pharmaceutical composition for treating cardiovascular diseases containing 3-(2,2,2-trimethylhydrazinium) propionate and gamma-butyrobetaine

Publications (2)

Publication Number Publication Date
DE69627160D1 true DE69627160D1 (de) 2003-05-08
DE69627160T2 DE69627160T2 (de) 2004-02-12

Family

ID=19736013

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69627160T Expired - Lifetime DE69627160T2 (de) 1995-08-21 1996-08-20 Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma-butyrobetain für die behandlung von herz-gefäss-erkrankungen

Country Status (11)

Country Link
US (1) US5859056A (de)
EP (1) EP0845986B1 (de)
JP (1) JP3072858B2 (de)
AT (1) ATE235901T1 (de)
CA (1) CA2229228C (de)
DE (1) DE69627160T2 (de)
EA (1) EA000472B1 (de)
ES (1) ES2196167T3 (de)
LV (1) LV11728B (de)
UA (1) UA44330C2 (de)
WO (1) WO1997006794A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV12491B (lv) * 1998-10-29 2000-12-20 Ivars KALVIŅŠ Farmaceitiska kompozīcija
FI114538B (fi) * 2001-01-12 2004-11-15 Finnfeeds Finland Ltd Glysiinibetaiinin käyttö verenpainetta alentavan tuotteen valmistukseen
LV12979B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
LV12978B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
JP4390134B2 (ja) 2003-11-05 2009-12-24 日本精工株式会社 ステアリング装置
LV13450B (en) * 2004-08-24 2006-11-20 Grindeks As Novel medicinal use of meldonium and pharmaceutical compositions thereof
LV14274B (lv) * 2009-06-25 2011-03-20 Grindeks, A/S Meldoniju saturošs kombinēts medicīniskais produkts
WO2010149654A1 (en) * 2009-06-25 2010-12-29 Grindeks, A Joint Stock Company Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt
LV14345B (lv) * 2009-10-22 2011-07-20 Grindeks, A/S 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai
US8940793B2 (en) 2011-04-27 2015-01-27 Jsc Grindeks 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease
JP5997762B2 (ja) * 2011-04-27 2016-09-28 グリンデクス, ア ジョイント ストック カンパニーGRINDEKS, a joint stock company 心血管疾患の治療における３−カルボキシ−ｎ−エチル−ｎ，ｎ−ジメチルプロパン−１−アミニウム塩の使用
LV14848B (lv) * 2012-10-25 2015-06-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompozīcija trimetilamīna-N-oksīda līmeņa pazemināšanai
GB201315321D0 (en) 2013-08-28 2013-10-09 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction Buffer
GB201521101D0 (en) 2015-11-30 2016-01-13 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction buffer
CN112180013B (zh) * 2020-09-29 2022-11-15 上海脉示生物技术有限公司 用于心肌梗死诊断的肠道微生物代谢标志物组合物及其检测方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198434B (it) * 1981-01-06 1988-12-21 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente gamma butirrobetaina per il trattamento di sindromi da carenze di carnitina
IT1210935B (it) * 1981-09-17 1989-09-29 Inst Orch Sinteza Akademi Nauk Composizione farmaceutica per il trattamento di malattie cardiovascolari.

Also Published As

Publication number Publication date
EP0845986A1 (de) 1998-06-10
CA2229228C (en) 2008-07-08
US5859056A (en) 1999-01-12
CA2229228A1 (en) 1997-02-27
EA199800160A1 (ru) 1998-08-27
EA000472B1 (ru) 1999-08-26
DE69627160T2 (de) 2004-02-12
EP0845986B1 (de) 2003-04-02
ATE235901T1 (de) 2003-04-15
LV11728B (en) 1997-08-20
JP3072858B2 (ja) 2000-08-07
JPH10512286A (ja) 1998-11-24
WO1997006794A1 (en) 1997-02-27
ES2196167T3 (es) 2003-12-16
UA44330C2 (uk) 2002-02-15
LV11728A (lv) 1997-04-20

Similar Documents

Publication Publication Date Title
DE69627160D1 (de) Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma-butyrobetain für die behandlung von herz-gefäss-erkrankungen
HUT77380A (hu) Kombinált gyógyszerkészítmény alkalmazása sclerosis multiplex (MS) és más demielizáló állapotok kezelésére
GEP20032958B (en) Adenosine Derivatives
DE69815122D1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
HUP9902105A2 (hu) Angiosztatikus dipeptideket tartalmazó gyógyászati készítmények és ezek alkalmazása
NO954694L (no) Doseringsform for antidepressiva
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
BG105342A (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
TW261532B (de)
IL116384A0 (en) Ylidene compounds and their preparation
KR960703593A (ko) (R)-암로디핀에 의한 평활근 세포 이동의 억제 (Inhibition of Smooth Muscle Cell Migration by (R)-Amlodipine)
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
CA2167257A1 (en) Use of Sertraline to Treat Cancer Patients
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
IL126795A (en) Pharmaceutical compositions for the treatment of substance abuse disorders comprising pyridyl- and pyrimidyl-piperazines
HUP0004647A2 (hu) Glükóz-amino-glükánok alkalmazása diabétesszel társult szembetegségek kezelésére szolgáló gyógyszerkészítmények előállítására
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
DK0457336T3 (da) Ny anvendelse af 4-carbamoyl-1-beta-D-ribofuranosylimidazolium-5-olat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: JOINT STOCK COMPANY "GRINDEKS", RIGA, LV

8381 Inventor (new situation)

Inventor name: KALVINSH, IVARS, 2169 SALASPILS, LV

Inventor name: VEVERIS, MARIS, 1035 RIGA, LV